Profound Medical Corp

Profound Medical Corp. and Telix Pharmaceuticals Limited have entered into a co-education agreement to advance PSMA-informed prostate care, the companies announced on October 9, 2026. The agreement establishes a framework to educate urologists, radiologists, nuclear medicine physicians and prostate cancer centers on the complementary roles of Telix's PSMA-targeting PET molecular imaging technologies, Gozellix and Illuccix, and Profound's MRI-guided, AI-powered, robotically-driven and incisionless TULSA-PRO platform across the prostate care continuum. Planned initiatives include participation in major scientific and medical society meetings, key opinion leader programs, educational summits, speaker programs and webinars, along with educational content, clinical case studies and best-practice materials. Profound said the collaboration increases its access to urologists across the U.S. and internationally through a strong strategic partner, and that it is also developing PSMA-PET-MR image-fusion capabilities for a planned future release of its Treatment Delivery Console software. Profound CEO and Chairman Arun Menawat said the agreement supports broader market development and could strengthen the clinical and economic value proposition of TULSA-PRO centers, while Telix Precision Medicine CEO Kevin Richardson said the collaboration aims to increase awareness of the complementary roles of PSMA-PET imaging and MRI-guided therapy.

Profound Medical Corp. closed at $6.87 per share on June 18, 2026, with a one-month return of 0.51% and a 52-week gain of 8.11%. Grow Funds highlighted the company in its first-quarter 2026 investor letter, noting its TULSA-PRO system is installed at 78 marquee hospitals with a pipeline of over 110 systems. The fund also pointed to higher hospital reimbursement compared to competitive procedures and favorable results from the Captain Trial versus radical prostatectomy. However, hedge fund holdings in Profound Medical fell to 6 at the end of the first quarter from 10 in the prior quarter, and the stock was not among the 40 most popular hedge fund stocks heading into 2026.